NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00781-3084-75 | 00781-3084 | Triamcinolone Hexacetonide | Aristospan | 5.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intralesional, Parenteral | Jul 29, 1969 | May 31, 2016 | In Use |
54868-3344-00 | 54868-3344 | Triamcinolone Hexacetonide | Aristospan | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Jul 12, 1994 | Jun 30, 2011 | No Longer Used | ||
64842-1025-02 | 64842-1025 | Trifluridine and Tipiracil | Lonsurf | 6.14 mg/1, 15.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Nov 11, 2015 | In Use | |
64842-1025-03 | 64842-1025 | Trifluridine and Tipiracil | Lonsurf | 6.14 mg/1, 15.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct 21, 2015 | In Use | |
64842-1020-03 | 64842-1020 | Trifluridine and Tipiracil | Lonsurf | 8.19 mg/1, 20.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct 21, 2015 | In Use | |
64842-1020-02 | 64842-1020 | Trifluridine and Tipiracil | Lonsurf | 8.19 mg/1, 20.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Nov 11, 2015 | In Use | |
64842-1020-01 | 64842-1020 | Trifluridine and Tipiracil | Lonsurf | 8.19 mg/1, 20.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct 7, 2015 | In Use | |
64842-1025-01 | 64842-1025 | Trifluridine and Tipiracil | Lonsurf | 6.14 mg/1, 15.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct 7, 2015 | In Use | |
73462-0101-01 | 73462-0101 | Trilaciclib | Cosela | 300.0 mg/20mL | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Intravenous | Feb 12, 2021 | In Use | |
52544-0153-02 | 52544-0153 | Triptorelin Pamoate | Trelstar | 3.75 mg/2mL | Hormonal Therapy | GnRH Agonist | Intramuscular | Jun 15, 2000 | Oct 31, 2018 | No Longer Used | |
52544-0188-76 | 52544-0188 | Triptorelin Pamoate | Trelstar | Hormonal Therapy | GnRH Agonist | Jun 29, 2001 | Oct 31, 2018 | No Longer Used | |||
52544-0189-76 | 52544-0189 | Triptorelin Pamoate | Trelstar | Hormonal Therapy | GnRH Agonist | Jun 15, 2000 | Oct 31, 2018 | No Longer Used | |||
00023-5902-04 | 00023-5902 | Triptorelin Pamoate | Trelstar | Hormonal Therapy | GnRH Agonist | Jun 15, 2000 | In Use | ||||
00023-5904-12 | 00023-5904 | Triptorelin Pamoate | Trelstar | Hormonal Therapy | GnRH Agonist | Jun 29, 2001 | In Use | ||||
52544-0156-02 | 52544-0156 | Triptorelin Pamoate | Trelstar | 22.5 mg/2mL | Hormonal Therapy | GnRH Agonist | Intramuscular | Mar 11, 2010 | Oct 31, 2018 | No Longer Used | |
00023-5906-23 | 00023-5906 | Triptorelin Pamoate | Trelstar | Hormonal Therapy | GnRH Agonist | Mar 11, 2010 | In Use | ||||
52544-0092-76 | 52544-0092 | Triptorelin Pamoate | Trelstar | Hormonal Therapy | GnRH Agonist | Mar 11, 2010 | Oct 31, 2018 | No Longer Used | |||
52544-0154-02 | 52544-0154 | Triptorelin Pamoate | Trelstar | 11.25 mg/2mL | Hormonal Therapy | GnRH Agonist | Intramuscular | Jun 29, 2001 | Oct 31, 2018 | No Longer Used | |
51144-0002-60 | 51144-0002 | Tucatinib | TUKYSA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | HER2 | Oral | Apr 17, 2020 | In Use | |
51144-0001-60 | 51144-0001 | Tucatinib | TUKYSA | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | HER2 | Oral | Apr 17, 2020 | In Use | |
51144-0002-12 | 51144-0002 | Tucatinib | TUKYSA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | HER2 | Oral | Apr 17, 2020 | In Use | |
73150-0200-12 | 73150-0200 | umbralisib | UKONIQ | 260.2 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 | Oral | Feb 5, 2021 | Jul 31, 2023 | No Longer Used |
69468-0151-04 | 69468-0151 | Uridine Triacetate | Vistogard | 951.0 mg/g | Ancillary Therapy | Chemoprotective | Antidote | Oral | Mar 1, 2016 | In Use | |
50633-0220-04 | 50633-0220 | Uridine triacetate | VISTOGARD | 951.0 mg/g | Ancillary Therapy | Chemoprotective | Antidote | Oral | Jul 31, 2024 | In Use | |
50633-0220-20 | 50633-0220 | Uridine triacetate | VISTOGARD | 951.0 mg/g | Ancillary Therapy | Chemoprotective | Antidote | Oral | Jul 31, 2024 | In Use |
Found 11120 results — Export these results